摘要
目的观察葡甘聚糖对正常大鼠和糖尿病大鼠的降血糖效果,测定糖尿病大鼠α-葡萄糖苷酶(α-糖苷酶)水平,初步探讨葡甘聚糖的作用机制,为临床应用提供理论依据。方法①将SD大鼠分为6组:正常组:给予生理盐水;阴性组:分别给予蔗糖、葡萄糖;阳性组:分别给予蔗糖、葡萄糖和伏格列波糖0.043mg·ml-1·100g体重-1;低剂量组:分别给予蔗糖、葡萄糖和葡甘聚糖0.05g·ml-1·100g体重-1;中剂量组:分别给予蔗糖、葡萄糖和葡甘聚糖0.1g·ml-1·100g体重-1;高剂量组:分别给予蔗糖、葡萄糖和葡甘聚糖0.5g·ml-1·100g体重-1。②雄性SD大鼠禁食24h后,腹腔注射20mg·ml-1·100g体重-1的四氧嘧啶水溶液,72h后从尾静脉取血,挑选出血糖浓度>10mmol/L的大鼠,随机分为5组:阴性组、阳性组分别给予生理盐水和上述剂量的伏格列波糖,低、中和高剂量组分别给予上述剂量的葡甘聚糖。③采用体内、体外实验测定大鼠的α糖苷酶活性。结果①对正常大鼠蔗糖耐量作用:阳性组与正常组血糖升高面积(△糖面积)的差异无显著性,均显著低于阴性组(P<0.05)。低、中和高剂量组的△糖面积显著高于阳性组(P<0.05),分别为阳性组的3.3、3.0和2.7倍,但仍显著低于阴性组(P<0.05)。低、中、高剂量组间的差异无显著性(P>0.05)。②对正常大鼠葡萄糖耐量作用:与?
Objective To explore the possible mechanism of glucomannan by investigating the antihyperglycemic effect on euglycemic and hyperglycemic rats and measurement of α-glucosidase level in diabetic rats.Methods ①The SD rats and alloxan-induced diabetic rats were divided into 6 groups, namely normal control group with normal saline only, negative control group with sucrose and glucose, positive control group with sucrose and glucose and Voglibose (0.043 mg·ml -1·100 g BW -1), low-dose group with sucrose and glucose and glucomannan (0.05 g·ml -1·100 g BW -1), median-dose group with sucrose and glucose and glucomannan (0.1 g·ml -1·100 g BW -1), high-dose group with sucrose and glucose and glucomannan ( 0.5 g·ml -1·100 g BW -1). Results ① Effect on sucrose tolerance test in normal rats, also expressed as ACU: All the rats with different doses of glucomannan had higher blood glucose level than that of the positive control group (P<0.05), which were 3.3, 3, and 2.7 folds higher respectively, but still lower than that in the negative control group (P<0.05) but no significant differences among low,modian and high-dose groups(P>0.05). ② Effect on glucose tolerance test in normal rats: After glucose loading, the blood glucose level elevated greatly in the negative control group, positive control group, as well as in all rats with different doses of glucomannan (P<0.05). The blood glucose levels expressed as AUC were of no statistical significances among the positive control group, low-dose group, median-dose group, high-dose group, and the negative control group. ③ Antihyperglycemic effect of glucomannan in alloxan induced diabetic rats: The amplitude of glucose reduction in the positive control group was 2.8 folds as that in negative control group, with statistical significance. The same occurred in both median-dose group and high-dose group, with 2.4 and 2.6 folds reduction as in the negative control group respectively(P>0.05). ④ Effect of glucomannan on sucrose tolerance test in alloxan-induced diabetic rats: The blood glucose level expressed as AUC were of no statistical significance among the positive control group, low-dose group, median-dose group, high-dose group, and negative control group (P<0.05). All were lower than that in the negative control group (P<0.05). ⑤ Effect of glucomannan on α-glucosidase activity (in vitro): The absorbance values in the blank groups were higher than that of the negative controls, while the absorbance in positive controls was similar to that in the blank groups. There were no statistical significance among the different dosages of glucomannan and the negative controls ⑥ Effect of glucomannan on α-glucosidase activity (in vivo): High-dose group and median-group had similar absorbance, which were slightly lower than the low-dose group, yet with no statistical significance among the three groups(P>0.05). All rats with glucomannan and the positive group had lower absorbance than the negative control group (P<0.05).Conclusion There was an antihyperglycemic effect of glucomannan acting in alloxan-induced diabetic rats, especially the blunting effect on postprandial glucose as well as an obvious α-glucosidase inhibitory effect.
出处
《上海医学》
CAS
CSCD
北大核心
2005年第5期406-411,共6页
Shanghai Medical Journal
